'We have yet to deploy it at the clinics. We plan to apply for its use when we have eligible patients,' says TalkMed
TalkMed Group, which specialises in cancer treatment, says that officials from the Ministry of Health "visited" three of its clinics concurrently on Aug 21, where the company's haematologists are "practising", to "find out" about the use of chimeric antigen receptors (CAR) T-cell therapy.
According to TalkMed, the health officials were attended by its nursing managers, operations executives and clinical research coordinator "who suggested for them to write in officially so that we could respond to their further queries in writing."
TalkMed, in its SGX filing on Aug 29, says that through its subsidiary, BioCell Innovations, it is now able to produce humanised CD-19 CAR, a form of cellular therapy for lymphoma and leukemia.
"We have yet to deploy it at the clinics. We plan to apply for its use when we have eligible patients," adds TalkMed.
TalkMed shares ended Aug 29 at 39 cents, down 2.5%.